Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy.
Date
2021-03-01ICR Author
Author
Ferguson, L
Ho, B
Weir, J
Francis, N
West, K
Rathbone, B
Larkin, J
Heelan, K
Type
Journal Article
Metadata
Show full item recordAbstract
We report a 73-year-old female with metastatic renal cell carcinoma who developed a widespread lichenoid reaction following nivolumab treatment. The timeline of the reaction strongly correlated with the nivolumab treatment and subsequent cessation. Our patient had cutaneous, mucosal, otic, ophthalmic and oesophageal involvement, demonstrating the potentially extensive nature of lichenoid reactions to anti-programmed cell death receptor-1 (anti-PD1) therapies. Although lichenoid reactions to anti-PD1 therapies are now well recognized, there have been no previous reports of otic or oesophageal involvement in the literature. Although cutaneous lichenoid reactions do not tend to be severe or treatment limiting, more widespread systemic lichenoid reactions are challenging to manage, particularly in the context of malignancy. This very unusual case highlights the importance of considering involvement beyond the skin in all lichenoid skin reactions.
Collections
Language
eng
Date accepted
2020-10-23
License start date
2021-03-01
Citation
Skin Health and Disease, 2021, 1 (1), pp. e8 -
Publisher
Wiley